Datasheet Inhibitors / Agonists / Screening Libraries a DRUG SCREENING EXPERT

Total Page：16

File Type：pdf, Size：1020Kb

Datasheet Inhibitors / Agonists / Screening Libraries A DRUG SCREENING EXPERT Product Name : Deslanoside Catalog Number : T8183 CAS Number : 17598-65-1 Molecular Formula : C47H74O19 Molecular Weight : 943.10 Description: Deslanoside is a rapidly acting cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms. Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Storage: 2 years -80°C in solvent; 3 years -20°C powder; DMSO 95mg/mL (100.73 mM), Need ultrasonic Solubility ( < 1 mg/ml refers to the product slightly soluble or insoluble ) Receptor (IC50) Na+/K+-ATPase In vitro Activity Deslanoside increases forearm blood flow and cardiac index and decreased heart rate concomitant with a marked decrease in skeletal muscle sympathetic nerve activity [1]. Deslanoside is a metabolite of Lanatoside C [3]. Reference 1. Hauptman PJ, et al. Digitalis. Circulation. 1999 Mar 9;99(9):1265-70. 2. Wang L, et al. Ontology-based systematical representation and drug class effect analysis of package insert-reported adverse events associated with cardiovascular drugs used in China. Sci Rep. 2017 Oct 23;7(1):13819. 4. Klys M, et al. Determination of deslanoside in antemortem and postmortem specimens. Unusual case report. Forensic Sci Int. 1990 Apr;45(3):231-8. FOR RESEARCH PURPOSES ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE. Information for product storage and handling is indicated on the product datasheet. Targetmol products are stable for long term under the recommended storage conditions. Our products may be shipped under different conditions as many of them are stable in the short-term at higher or even room temperatures. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, please follow the storage recommendations on the product data sheet. [email protected] | Tel: +1-781-999-4286 | www.targetmol.com.

Copy Link

Recommended publications

Combination of Pretreatments with Acetic Acid and Sodium Methoxide for Efficient Digoxin Preparation from Digitalis Glycosides in Digitalis Lanata Leaves
Pharmacology & Pharmacy, 2016, 7, 200-207 Published Online May 2016 in SciRes. http://www.scirp.org/journal/pp http://dx.doi.org/10.4236/pp.2016.75026 Combination of Pretreatments with Acetic Acid and Sodium Methoxide for Efficient Digoxin Preparation from Digitalis Glycosides in Digitalis lanata Leaves Yasuhiko Higashi*, Yukari Ikeda, Youichi Fujii Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, Japan Received 21 April 2016; accepted 28 May 2016; published 31 May 2016 Copyright © 2016 by authors and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/ Abstract We previously developed an HPLC method for determination of lanatoside C, digoxin and α-acetyl- digoxin in digitalis glycosides isolated from Digitalis lanata leaves. Here, we present an improved HPLC-UV method to determine those compounds and deslanoside. We used the improved method to examine the effects of various pretreatments on the amounts of the four compounds isolated from the leaves, with the aim of maximizing the yield of digoxin. Leaves were extracted with 50% methanol, followed by clean-up on a Sep-Pak C18 cartridge prior to HPLC analysis. The amounts of lanatoside C, digoxin and α-acetyldigoxin per 100 mg of the leaves without pretreatment were 115.6, 7.45 and 23.8 μg, respectively (deslanoside was not detected). Pretreatment with acetic ac- id, which activated deglucosylation mediated by digilanidase present in the leaves, increased the amounts of digoxin and α-acetyldigoxin, while lanatoside C and deslanoside were not detected. Pretreatment with sodium methoxide, which hydrolyzed lanatoside C to deslanoside, increased the yields of deslanoside and digoxin, while lanatoside C and α-acetyldigoxin were not detected.
[Show full text]
Pharmacokinetics, Bioavailability and Serum Levels of Cardiac Glycosides
View metadata, citation and similar papers at core.ac.uk brought to you by CORE JACCVol. 5, No.5 provided by Elsevier - Publisher43A Connector May 1985:43A-50A Pharmacokinetics, Bioavailability and Serum Levels of Cardiac Glycosides THOMAS W. SMITH, MD, FACC Boston. Massachusetts Digoxin, the cardiac glycoside most frequently used in bioavailability of digoxin is appreciably less than that of clinical practice in the United States, can be givenorally digitoxin, averaging about two-thirds to three-fourths of or intravenously and has an excretory half-life of 36 to the equivalent dose given intravenously in the case of 48 hours in patients with serum creatinine and blood currently available tablet formulations. Recent studies urea nitrogen values in the normal range. Sincethe drug have shown that gut ftora of about 10% of patients re is excreted predominantly by the kidney, the half-life is duce digoxin to a less bioactive dihydro derivative. This prolonged progressivelywithdiminishingrenal function, process is sensitiveto antibiotic administration, creating reaching about 5 days on average in patients who are the potential for important interactions among drugs. essentially anephric. Serum protein binding of digoxin Serum or plasma concentrations of digitalis glycosides is only about 20%, and differs markedly in this regard can be measured by radioimmunoassay methods that are from that of digitoxin, which is 97% bound by serum nowwidelyavailable, but knowledgeofserum levelsdoes albumin at usual therapeutic levels. Digitoxin is nearly not substitute for a sound working knowledge of the completely absorbed from the normal gastrointestinal clinical pharmacology of the preparation used and care tract and has a half-lifeaveraging 5 to 6 days in patients ful patient follow-up.
[Show full text]
Multidose Evaluation of 6,710 Drug Repurposing Library Identifies Potent SARS-Cov-2 Infection Inhibitors in Vitro and in Vivo
bioRxiv preprint doi: https://doi.org/10.1101/2021.04.20.440626; this version posted April 22, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Multidose evaluation of 6,710 drug repurposing library identifies potent SARS-CoV-2 infection inhibitors In Vitro and In Vivo. JJ Patten1, P. T. Keiser 1, D. Gysi2,3, G. Menichetti 2,3, H. Mori 1, C. J. Donahue 1, X. Gan 2,3, I. Do Valle 2, , K. Geoghegan-Barek 1, M. Anantpadma 1,4, J. L. Berrigan 1, S. Jalloh1, T. Ayazika1, F. Wagner6, M. Zitnik 2, S. Ayehunie6, D. Anderson1, J. Loscalzo3, S. Gummuluru1, M. N. Namchuk7, A. L. Barabasi2,3,8, and R. A. Davey1. Addresses: 1. Department of Microbiology, Boston University School of Medicine and NEIDL, Boston University, Boston, MA, 02118, USA. 2. Center for Complex Network Research, Northeastern University, Boston, Massachusetts 02115, USA. 3. Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. 4. present address: Analytical Development, WuXi Advanced Therapies, Philadelphia, PA, 19112, USA. 5. Center for the Development of Therapeutics, Broad Institute of Harvard and MIT, Cambridge, MA, 02142, USA. 6. MatTek Corporation, Ashland, MA 01721, USA. 7. Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA. 02115, USA. 8. Department of Network and Data Science, Central European University, Budapest 1051, Hungary. Abstract The SARS-CoV-2 pandemic has caused widespread illness, loss of life, and socioeconomic disruption that is unlikely to resolve until vaccines are widely adopted, and effective therapeutic treatments become established.
[Show full text]
Marrakesh Agreement Establishing the World Trade Organization
No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
[Show full text]
(12) Patent Application Publication (10) Pub. No.: US 2009/0246185 A1 Kishida Et Al
US 20090246185A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0246185 A1 Kishida et al. (43) Pub. Date: Oct. 1, 2009 (54) CARDIAC DYSFUNCTION-AMELIORATING (30) Foreign Application Priority Data AGENT OR CARDAC FUNCTION-MANTAININGAGENT Mar. 13, 2006 (JP) ................................. 2006-066992 Nov. 21, 2006 (JP) ................................. 2006-314034 (75) Inventors: Hideyuki Kishida, Hyogo (JP); O O Kenji Fujii, Hyogo (JP); Hiroshi Publication Classification Kubo, Hyogo (JP); Kazunori (51) Int. Cl. Hosoe, Hyogo (JP) A6II 3L/22 (2006.01) CD7C 43/23 (2006.01) Correspondence Address: A6IP 9/00 (2006.01) SUGHRUE MION, PLLC (52) U.S. Cl. ........................................ 424/94.1:568/651 2100 PENNSYLVANIA AVENUE, N.W., SUITE 8OO (57) ABSTRACT WASHINGTON, DC 20037 (US) An object of the present invention is to provide a highly safe oral composition Superior in a cardiac dysfunction-amelio (73) Assignee: KANEKA CORPORATION, rating or cardiac function-maintaining action. The present OSAKA-SHI, OSAKA (JP) inventors have conducted intensive studies in an attempt to solve the aforementioned problems and found that use of (21) Appl. No.: 12/282,448 particularly, reduced coenzyme Q10 from among highly safe coenzyme Q affords a composition useful for amelioration of (22) PCT Filed: Mar. 9, 2007 cardiac dysfunction and maintenance of cardiac function. Accordingly, the present invention provides a cardiac dys (86). PCT No.: PCT/UP2007/O54.643 function-ameliorating agent or cardiac function-maintaining agent containing reduced coenzyme Qas an active ingredient, S371 (c)(1), and a pharmaceutical product, a food, an animal drug, a feed (2), (4) Date: Dec. 23, 2008 and the like, which contain the agent.
[Show full text]
Eiichi Kimura, MD, Department of Internal Medicine, Nippon Medical
Effect of Metildigoxin (ƒÀ-Methyldigoxin) on Congestive Heart Failure as Evaluated by Multiclinical Double Blind Study Eiichi Kimura,* M.D. and Akira SAKUMA,** Ph.D. In Collaboration with Mitsuo Miyahara, M.D. (Sapporo Medi- cal School, Sapporo), Tomohiro Kanazawa, M.D. (Akita Uni- versity School of Medicine, Akita), Masato Hayashi, M.D. (Hiraga General Hospital, Akita), Hirokazu Niitani, M.D. (Showa Uni- versity School of Medicine, Tokyo), Yoshitsugu Nohara, M.D. (Tokyo Medical College, Tokyo), Satoru Murao, M.D. (Faculty of Medicine, University of Tokyo, Tokyo), Kiyoshi Seki, M.D. (Toho University School of Medicine, Tokyo), Michita Kishimoto, M.D. (National Medical Center Hospital, Tokyo), Tsuneaki Sugi- moto, M.D. (Faculty of Medicine, Kanazawa University, Kana- zawa), Masao Takayasu, M.D. (National Kyoto Hospital, Kyoto), Hiroshi Saimyoji, M.D. (Faculty of Medicine, Kyoto University, Kyoto), Yasuharu Nimura, M.D. (Medical School, Osaka Uni- versity, Osaka), Tatsuya Tomomatsu, M.D. (Kobe University, School of Medicine, Kobe), and Junichi Mise, M.D. (Yamaguchi University, School of Medicine, Ube). SUMMARY The efficacy on congestive heart failure of metildigoxin (ƒÀ-methyl- digoxin, MD), a derivative of digoxin (DX), which had a good absorp- tion rate from digestive tract, was examined in a double blind study using a group comparison method. After achieving digitalization with oral MD or intravenous deslanoside in the non-blind manner, mainte- nance treatment was initiated and the effects of orally administered MD and DX were compared. MD was administered in 44 cases , DX in 42. The usefulness of the drug was evaluated after 2 weeks , taking into account the condition of the patient and the ease of administration .
[Show full text]
Radioimmunoassay
Radioimmunoassay Measurement of Serum Cardiac Glycoside Levels: Using Pharmacologic Principles to Solve Crossreactivity Problems Thomas J. Persoon The University of Iowa, Iowa City, Iowa Laboratories performing analyses for serum cardiac Results glycosides are sometimes faced with the problem of dis Data collected in our laboratory are similar to those tinguishing between digoxin and digitoxin in a specimen. published by Kuno-Sakai. Tables 3 and 4 show the The antibodies to the cardiac glycosides supplied with measured concentrations of digoxin and digitoxin from radioimmunoassay kits for these drugs have some patient sera known to contain only one drug. Figure 1 measurable degree of cross reactivity. Therapeutic levels is a plot of measured digoxin levels versus actual of digitoxin are approximately ten times greater than digitoxin concentration of serum digitoxin standards. those of digoxin, and the half-lives of these drugs in The slope and intercept of the line were determined by serum differ by a factor of four. These facts have been the linear least-squares technique. combined into a series of rules which allow the technologist to distinguish between digoxin and digitoxin Discussion in a sample and provide a level of the drug that has been corrected for crossreactivity. Figure 2 shows the chemical structures of four cardiac glycosides: digoxin, digitoxin, cedilanid, and In 1972 Edmonds et al. ( 1) published data on the crossreactivity of digitoxin in the digoxin radioim TABLE 1. Crossreactivity of Digitoxin in Digoxin RIA munoassay (Tables 1 and 2). They showed the slopes Measured level of of digoxin-digitoxin cross reactivity plots to be linear. Digitoxin added (ng/mll digoxin (ng/mll Kuno-Sakai et al.
[Show full text]
(12) Patent Application Publication (10) Pub. No.: US 2004/0077723 A1 Granata Et Al
US 2004OO77723A1. (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0077723 A1 Granata et al. (43) Pub. Date: Apr. 22, 2004 (54) ESSENTIALN-3 FATTY ACIDS IN CARDIAC (30) Foreign Application Priority Data INSUFFICIENCY AND HEART FAILURE THERAPY Jan. 25, 2001 (IT)............................... MI2OO1 AOOO129 (76) Inventors: Francesco Granata, Milan (IT): Publication Classification Franco Pamparana, Milan (IT); 7 Eduardo Stragliotto, Milan (IT) (51) Int. Cl." .................................................. A61K 31/202 (52) U.S. Cl. .............................................................. 514/560 Correspondence Address: ARENT FOX KINTNER PLOTKIN & KAHN 1050 CONNECTICUT AVENUE, N.W. (57) ABSTRACT SUTE 400 WASHINGTON, DC 20036 (US) The present invention concerns a method of therapeutic prevention and treatment of a heart disease chosen from (21) Appl. No.: 10/451,623 cardiac insufficiency and heart failure including the admin istration of an essential fatty acid containing a mixture of (22)22) PCT Fed: Jan. 16,9 2002 eicosapentaenoicp acid ethvily ester (EPA) and docosa hexaenoic acid ethyl ester (DHA), either alone or in com (86) PCT No.: PCT/EP02/00507 bination with another therapeutic agent. US 2004/0077723 A1 Apr. 22, 2004 ESSENTIAL, N-3 FATTY ACIDS IN CARDIAC and inhibitors of phosphodiesterase, arteriolar and Venular INSUFFICIENCY AND HEART FAILURE vasodilators, e.g. hydralazine and isosorbide dinitrate, beta THERAPY blockers e.g. metoprolol and bisoprolol and digitalis deriva 0001. The present invention
[Show full text]
65: Cardioactive Steroids
65: Cardioactive Steroids Jason B. Hack HISTORY AND EPIDEMIOLOGY The Ebers Papyrus provides evidence that the Egyptians used plants containing cardioactive steroids (CASs) at least 3000 years ago. However, it was not until 1785, when William Withering wrote the first systemic account about the effects of the foxglove plant, that the use of CASs was more widely accepted into the Western apothecary. Foxglove, the most common source of plant CAS, was initially used as a diuretic and for the treatment of “dropsy” (edema), and Withering eloquently described its “power over the motion of the heart, to a degree yet unobserved in any other medicine.”124 Subsequently, CASs became the mainstay of treatment for congestive heart failure and to control the ventricular response rate in atrial tachydysrhythmias. Because of their narrow therapeutic index and widespread use, both acute and chronic toxicities remain important problems.84 According to the American Association of Poison Control Centers data, between the years 2006 and 2011, there were approximately 8000 exposures to CAS-containing plants with one attributable deaths and about 14,500 exposures to CAS-containing xenobiotics resulting in more than100 deaths (Chap. 136). Pharmaceutically induced CAS toxicity is typically encountered in the United States from digoxin; other internationally available but much less commonly used preparations are digitoxin, ouabain, lanatoside C, deslanoside, and gitalin. Digoxin toxicity most commonly occurs in patients at the extremes of age or those with chronic kidney disease (CKD). In children, most acute overdoses are unintentional by mistakenly ingesting an adult’s medication, or iatrogenic resulting from decimal point dosing errors (digoxin is prescribed in submilligrams, inviting 10-fold dosing calculation errors), or the elderly who are at risk for digoxin toxicity, most commonly from interactions with another medication in their chronic regimen or indirectly as a consequence of an alteration in the absorption or elimination kinetics.
[Show full text]
The Effects of Ouabain in Lambs with Depressed Myocardial Function
Pediatr. Res. 16: 357-361 (1982) The Effects of Ouabain in Lambs with Depressed Myocardial Function WILLIAM BERMAN, JR.,'"' STEVEN M. YABEK, AND RAMONA SHORTENCARRIER University of New Mexico, School of Medicine, Department of Pediatrics, Cardiology Division, Albuquerque, New Mexico, USA Summary mesh pouch, sewn to the skin. Animals were treated postopera- tively with 50,000 units/kg/day of penicillin and 15 mg/kg/day The effects of ouabain infusion were tested in six lambs before of Kanamycin, given intramuscularly. Studies were performed 48 and after depression of myocardial function by halothane anesthe- h or more after surgery. sia. Halothane reduced the left ventricular rate of pressure rise (dp/dt), stroke work, and stroke volume; the ratio of preejection RESTING STUDIES period to left ventricular ejection time rose. Heart rate and systemic vascular resistance did not change. Before halothane, Baseline measurements. Resting measurements of hemodynamic ouabain infusion did not alter the hemodynamic variables mea- function were made while the lambs rested quietly, blind- sured. After myocardial depression, ouabain infusion returned dp/ folded in an open cage. Physiologic data were recorded on a dt, stroke work, stroke volume and the ratio of preejection period Beckman R-611 direct writing recorder at paper speeds of 2.5, 10, to left ventricular ejection time to control levels. Pacing studies 25, 100 and 200 mm/sec. Arterial pH, Pcoz, Pop and hematocrit showed a biphasic relationship between left ventricular dp/dt and were measured on each study day. Aortic and right atrial pressures heart rate. Maximal dp/dt occurred at a heart rate 42 beats/min were recorded with Statham P23DB strain gauges.
[Show full text]
Search Strategy: Database: Ovid MEDLINE(R) 1946 to Present with Daily Update ------1 Exp Ventricular Dysfunction, Right/ 2 (Right.Ab,Ti,Sh
Search Strategy: Database: Ovid MEDLINE(R) 1946 to Present with Daily Update -------------------------------------------------------------------------------- 1 exp Ventricular Dysfunction, Right/ 2 (Right.ab,ti,sh. and ((cardiac* or ventri* or myocardi* or heart* or chamber*) adj3 (fail* or output* or out-put* or function* or insufficien* or systol* or pump* or dys-function* or dysfunction*)).mp.) or (cor adj pulmonal*).ti,ab,sh. 3 cardiotonic*.ti,ab,sh. or exp Cardiotonic Agents/ 4 exp cardenolides/ or exp digitoxin/ or exp acetyldigitoxins/ or exp digitoxigenin/ or exp digoxin/ or exp acetyldigoxins/ or exp digoxigenin/ or exp medigoxin/ or exp strophanthins/ or exp cymarine/ or exp ouabain/ or exp strophanthidin/ or exp cardiac glycosides/ or exp bufanolides/ or exp digitalis glycosides/ or exp lanatosides/ or exp deslanoside/ 5 (cardinolide* or digitox* or acetyldig* or digoxin* or medigox* or strophanthidin* or cymarin* or ouabain* or strophanthidin* or (cardiac* adj glycoside*) or bufanolide* or lanatoside* or deslanosid*).mp. 6 (1 or 2) and (3 or 4 or 5) *************************** Embase.com #1. 'right ventricular failure'/exp #2. right AND (cardiac* OR ventri* OR myocardi* OR heart* OR chamber*) NEAR/3 (fail* OR output* OR function* OR insufficien* OR systol* OR pump* OR dysfunction*) OR cor NEXT/1 pulmonal* #3. cardiotonic* #4. 'cardenolides'/exp OR 'cardenolides' OR 'digitoxin'/exp OR 'digitoxin' OR 'acetyldigitoxins'/exp OR 'acetyldigitoxins' OR 'digitoxigenin'/exp OR 'digitoxigenin' OR 'digoxin'/exp OR 'digoxin' OR 'acetyldigoxins'/exp OR 'acetyldigoxins' OR 'digoxigenin'/exp OR 'digoxigenin' OR 'medigoxin'/exp OR 'medigoxin' OR 'strophanthins'/exp OR 'strophanthins' OR 'cymarine'/exp OR 'cymarine' OR 'ouabain'/exp OR 'ouabain' OR 'strophanthidin'/exp OR 'strophanthidin' OR 'cardiac glycosides'/exp OR 'cardiac glycosides' OR 'bufanolides'/exp OR 'bufanolides' OR 'digitalis glycosides'/exp OR 'digitalis glycosides' OR 'lanatosides'/exp OR 'lanatosides' OR 'deslanoside'/exp OR 'deslanoside' #5.
[Show full text]
LETTER Doi:10.1038/Nature09978
LETTER doi:10.1038/nature09978 Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORct activity Jun R. Huh1, Monica W. L. Leung1*, Pengxiang Huang2*, Daniel A. Ryan3, Michael R. Krout3, Raghu R. V. Malapaka4, Jonathan Chow1,5, Nicolas Manel1{, Maria Ciofani1, Sangwon V. Kim1, Adolfo Cuesta1,5, Fabio R. Santori1, Juan J. Lafaille1, H. Eric Xu4, David Y. Gin3, Fraydoon Rastinejad2 & Dan R. Littman1,5 1 CD4 T helper lymphocytes that express interleukin-17 (TH17 activity. These data justify utilization of the heterologous system to cells) have critical roles in mouse models of autoimmunity, and identify small molecules that modulate RORc activity. there is mounting evidence that they also influence inflammatory We next performed a chemical screen with 4,812 compounds and processes in humans. Genome-wide association studies in humans identified digoxin as a specific inhibitor for RORc transcriptional have linked genes involved in TH17 cell differentiation and function activity (Fig. 1a). Digoxin inhibited RORc (Fig. 1b and Supplemen- with susceptibility to Crohn’s disease, rheumatoid arthritis and tary Fig. 2a) with a half-maximum inhibitory concentration (IC50) 1–3 psoriasis . Thus, the pathway towards differentiation of TH17 cells value of 1.98 mM. Inhibition of RORc activity by digoxin was specific, and, perhaps, of related innate lymphoid cells with similar effector as there was no effect on the transcriptional activity of VP16 or of the functions4,5, is an attractive target for therapeutic applications. related nuclear hormone receptors RORa and DHR3 (Fig. 1c). Digoxin Mouse and human TH17 cells are distinguished by expression of did not inhibit the activity of other nuclear hormone receptors, includ- the retinoic acid receptor-related orphan nuclear receptor RORct, ing Caenorhabditis elegans DAF-12, human androgen receptor and which is required for induction of IL-17 transcription and for the LXRa (Supplementary Fig.
[Show full text]